BioSpace News Archive

Galderma to Present New Data From Leading Aesthetics Portfolio and Launch * RESTYLANE ® EYELIGHT™ at AMWC 2021

Appointments represent Jaguar’s focus on forging business development partnerships to advance crofelemer development and access and preparing for the expected near-term approval and commercialization of crofelemer prescription product for chemotherapy-induced diarrhea in dogs. Company to host investor webcast Monday, September 20th at 8:30 a.m. Eastern;

Altamira Therapeutics Ltd. today announced that its Chairman and CEO, Thomas Meyer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference, to be held virtually September 13-15, 2021.

Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), today announced that it has selected Treatment-Resistant Depression (“TRD”) and End of Life Angst as initial target indications for its lead clinical candidate, MSP-1014.

Trinity Biotech plc today announced results for the quarter ended June 30, 2021.

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will be presenting at the following virtual investor conferences to take place in September, 2021.

Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 23rd Global Investment Conference.

Veranome Biosystems announced commercial availability of the VSA-1 instrument for highly multiplexed, single cell spatial analysis.

Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ELX-02, a drug candidate intended to treat cystic fibrosis patients with nonsense mutations. ELX-02 is currently in Phase 2 clinical trials in CF patients affected by nonsense mutations in the CFTR (CF transmembrane conductance regulator) gene for whom there are no effective disease modifying therapies.

Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the final clinical results from its Phase I clinical study of Lomecel-B in Hypoplastic Left Heart Syndrome (HLHS), a rare and life-threatening congenital heart disease.